Medical management of hyperlipidemia/dyslipidemia

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 6, 2003, Pages 2445-2461

  Kreisberg, Robert A ^a   Oberman, Albert ^b  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIOXIDANT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBOHYDRATE; COLESEVELAM; CYANOCOBALAMIN; EZETIMIBE; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FOLIC ACID; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PRAVASTATIN; PYRIDOXINE; SIMVASTATIN; SITOSTANOL; SOYBEAN PROTEIN; STANOL ESTER; STEROL; THIAZOLIDINE DERIVATIVE; VITAMIN;

AGE DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG EFFECT; DYSLIPIDEMIA; EXERCISE; HEART PROTECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; KIDNEY FAILURE; LIFESTYLE; NUTRIENT SUPPLY; NUTRITION; OXIDATIVE STRESS; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SEX RATIO; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT REDUCTION;

GLYCINE MAX; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0037630435     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030388     Document Type: Review

References (177)

1. Ross R 1999 Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126
2. Libby P, Ridker PM, Maseri A 2002 Inflammation and atherosclerosis. Circulation 105:1135-1143
3. Geng Y-J, Libby P 2002 Progression of atheroma. A struggle between death and procreation. Arterioscler Thromb Vasc Biol 22:1370-1380
4. Schoenhagen P, Tuzcu EM, Ellis SG 2002 Plaque vulnerability, plaque rupture, and acute coronary syndromes. (Multi)-focal manifestation of a systemic disease process. Circulation 106:760-762
5. Forrester JS 2002 Prevention of plaque rupture: a new paradigm of therapy. Ann Intern Med 137:823-833
6. Ward MR, Pasterkamp G, Yeung AC, Borst C 2000 Arterial remodeling. Mechanisms and clinical implications. Circulation 102:1186-1191
7. Kreisberg RA, Oberman A 2002 Lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies. J Clin Endocrinol Metab 87:423-437
8. Forrester JS, Shah PK 1997 Lipid lowering versus revascularization. An idea whose time (for testing) has come. Circulation 96:1360-1362
9. Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 288:321-341
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 2001 Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285:2486-2497
11. Ridker PM 2003 Clinical application of c-reactive protein for cardiovascular disease detection and prevention. Circulation 107:363-369
12. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon III RO, Criqui M, Fadl UU, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith Jr SC, Taubert K, Tracy RP, Vinicor F 2003 Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for health care professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499-511
13. Knopp RH, Retzlaff B, Walden C, Fish B, Buck B, McCann B 2000 One-year effects of increasingly fat-restricted, carbohydrate-enriched diets on lipoprotein levels in free-living subjects. Proc Soc Exp Biol Med. 225:191-199
14. Turley ML, Skeszff CM, Mann JI, Cox B 1998 The effect of a low-fat, high-carbohydrate diet on serum high density lipoprotein cholesterol and triglyceride. Eur J Clin Nutr 52:728-732
15. Lichtenstein AH, Deckelbaum RJ, for the American Heart Association Nutrition Committee 2001 Stanol/sterol ester-containing foods and blood cholesterol levels. A statement for health care professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation 103:1177-1179
16. Denke MA, Adams-Huet B, Nguyen AT 2000 Individual cholesterol variation in response to a margarine- or butter-based diet: A study in families. JAMA 284:2740-2747
17. Shikany JM, White GL 2000 Southern Medical Journal. Dietary guidelines for chronic disease prevention. Southern Medical Journal. 93:1138-1151
18. Erdman Jr JW, for the AHA Nutrition Committee 2000 Soy protein and cardiovascular disease: a statement for healthcare professionals from the Nutrition Committee of the AHA. Circulation 102:2555-2559
19. Clarkson TB 2002 Soy, soy phytoestrogens and cardiovascular disease. J Nutr 132:566S-569S
20. Schaefer EJ 2002 Lipoproteins, nutrition, and heart disease. Am J Clin Nutr 75:191-212
21. Hu FB, Willett WC 2002 Optimal diets for prevention of coronary heart disease. JAMA. 288:2569-2578
22. Kris-Etherton P, Daniels SR, Eckel RH, Engler M, Howard BV, Krauss RM, Lichtenstein AH, Sacks F, St. Joer S, Stampfer M, for the American Heart Association Nutrition Committee Speakers and Discussants 2001 Summary of the Scientific Conference on Dietary Fatty Acids and Cardiovascular Health: conference summary from the Nutrition Committee of the American Heart Association. Circulation 103:1034-1039
23. Connor WE, Lin DS 1982 The effect of shellfish in the diet upon the plasma lipid levels in humans. Metabolism 31:1046-1051
24. Childs MT, Dorsett CS, Failor A, Roidt L, Omenn GS 1987 Effect of shellfish consumption on cholesterol absorption in normolipidemic men. Metabolism 36:31-35
25. Lada AT, Rudell LL 2003 Dietary monounsaturated versus polyunsaturated fatty acids: which is really better for protection from coronary heart disease? Curr Opin Lipidol 14:41-46
26. Kris-Etherton PM, Harris WS, Appel LJ, for the Nutrition Council of the AHA 2002 Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106:2747-2757
27. Kris-Etherton PM 1999 AHA Science Advisory. Monounsaturated fatty acids and risk of cardiovascular disease. American Heart Association. Nutrition Committee. Circulation 100:1253-1258
28. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM 1989 Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet 2:757-761
29. 1999 Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell-Infarto miocardico. Lancet 354:447-455
30. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N 1999 Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 99:779-785
31. Krauss RM, Eckel RH, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman Jr JW, Kris-Etherton P, Goldberg U, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson K, Wylie-Rosett J, St. Jeor S, Suttie J, Tribble DH, Bazzarre TL 2000 AHA dietary guideline, revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 102:2284-2299
32. Howard BV, Wylie-Rosett J 2002 Sugar and cardiovascular disease: a statement for healthcare professionals from the Committee on Nutrition of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation 106:523-527
33. Ludwig DS 2002 The glycemic index: physiologic mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA 287:2414-2423
34. Malinow MR, Bostom AG, Krauss RM 1999 Homocyst(e)ine, diet and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 99:178-182
35. The Homocysteine Studies Collaboration 2002 Homocysteine and risk of ischemic heart disease and stroke. JAMA 288:2015-2022
36. DeBree A, Verschuren WMM, Kromhout D, Kluijmans AJ, Blom JH 2002 Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 54:599-618
37. Dierkes J, Westphal S, Kunstmann S, Banditt P, Lössner A, Luley C 2001 Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate. Atherosclerosis 158:161-164
38. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH 1999 The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 340:1449-1454
39. Wahle KWJ 2002 Atherosclerosis: cell biology and lipoproteins. Curr Opin Lipidol 13:347-349
40. Marchioli R, Schweiger C, Levantesi G, Tavazzi L, Valagussa F 2001 Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data. Lipids 36:S53-S63
41. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P 2000 Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:154-160
42. Heart Protection Study Collaborative Group 2002 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
43. Brown BG, Zhao X-Q, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albert JJ 2001 Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention or coronary disease. N Engl J Med 345:1583-1592
44. Kris-Etherton PM, Etheron TD, Carlson J, Gardner C 2002 Recent discoveries in inclusive food-based approaches and dietary patterns for reduction in risk for cardiovascular disease. Curr Opin Lipidol 13:397-407
45. Rimm EB, Stampfer MJ 2002 Wine, beer, and spirits: are they really horses of a different color? Circulation 105:2806-2807
46. Mukamal KJ, Maclure M, Muller JE, Sherwood JB, Mittleman MA 2001 Prior alcohol consumption and mortality following acute myocardial infarction. JAMA 285:1965-1970
47. Albert MA, Glynn RJ, Ridker PM 2003 Alcohol consumption and plasma concentration of c-reactive protein. Circulation 107:443-447
48. Goldberg I, Mosca L, Piano MR, Fisher EA 2001 Wine and your heart: a science advisory for heaithcare professionals from the Nutrition Committee, Council on Epidemiology and Prevention and Council on Cardiovascular Nursing of the American Heart Association. Circulation 103:472-475
49. Corder R, Douthwaite JA, Lees DM, Khan NQ, Viseu dos Santos AC, Wood EG, Carrier MJ 2001 Endothelin-1 synthesis reduced by red wine. Nature 414:863-864
50. Mukamal KJ, Conigrave KM, Mittleman MA, Camargo CA, Stampfer MJ, Willett WC, Rimm EB 2003 Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 348:109-118
51. Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, Forstermann U 2002 Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 106:1652-1658
52. Ackermann RT, Mulrow CD, Ramirez GM, Gardner CD, Morbidoni L, Lawrence VA 2001 Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med 161:813-824
53. Kris-Etherton PM, Zhao G, Binkoski AE, Coval SM, Etherton TD 2001 The effects of nuts on coronary heart disease risk. Nutr Rev 59:103-111
54. Zambon D, Sabate J, Munoz S, Campero B, Casals E, Merlos M, Laguna JC, Ros E 2000 Substituting waInuts for monounsaturated fat improves the serum lipid profile of hypercholesterolemic men and women. A randomized crossover trial. Ann Intern Med 132:538-546
55. Fraser GE 1999 Nut consumption, lipids, and risk of a coronary event. Clin Cardiol 22(7 Suppl):III-11-III-15
56. Eckel RH 1999 The importance of timing and accurate interpretation of the benefits of weight reduction on plasma lipids. Obes Res 7:227-228
57. Wolf RN, Grundy SM 1983 Influence of weight reduction on plasma lipoproteins in obese patients. Arteriosclerosis 3:160-169
58. Westman EC, Yancy WS, Guyton JS 2002 Effect of a low-carbohydrate ketogenic diet program on fasting lipid subfractions. Circulation 106:727
59. Myers J, Praskash M, Froelicher V, Do D, Partington S, Atwood JE 2002 Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 346:793-801
60. Tanasescu M, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, Hu FB 2002 Exercise type and intensity in relation to coronary heart disease in men. JAMA 288:1994-2000
61. Tall AR 2002 Exercise to reduce cardiovascular risk - how much is enough? N Engl J Med 347:1522-1524
62. Durstine JL, Grandjean PW, Cox CA, Thompson PD 2002 Lipids, lipoproteins, and exercise. J Cardiopulm Rehabil 22:385-398
63. Pettit DS, Amgrimsson SA, Cureton KJ 2003 Effect of resistance exercise on postprandial lipemia. J Appl Physiol 94:694-700
64. Gotto Jr AM, Farmer JA 2001 Pleiotropic effects of statins: do they matter? Curr Opin Lipidol 12:391-394
65. 2002 Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288:2998-3007
66. Pasternak RC 2002 The ALLHAT Lipid Lowering Trial: less is less. JAMA 288:3042-3044
67. Pasternak RC, Grundy SM, Smith Jr SC, Cleeman JI, Bairey-Merz CN, Lenfant C 2002 ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. J Am Coll Cardiol 40:567-572
68. Knopp RH 1999 Drug treatment of lipid disorders. N Engl J Med 341:498-511
69. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, England JD 2002 Statin-associated myopathy with normal creatine kinase levels. The Scripps Mercy Clinical Research Center. Ann Intern Med 137:581-585
70. Grundy SM 2002 Hyperlipidemia. PDR clinical handbook. 1st ed. Montvale, NJ: Thomson Medical Economics Company
71. Simons J January 20, 2003 The $10 billion pill. Fortune; 58-68
72. Stein EA, Lane M, Laskaryewski D 1998 Comparison of statins in hypertriglyceridemia. Am J Cardiol 81:66B-69B
73. Wierzbicki AS, Mikhailidis DP 2002 Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Int J Cardiol 84:53-57
74. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ 2002 Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 164:361-369
75. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP, for the Ezetimibe Study Group 2002 Efficacy and safety of a potent new selective cholesterol absorption inhibitor, Ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 90:1092-1097
76. Gylling H, Miettinen TA 2002 Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients. Atherosclerosis 160:477-481
77. Cromwell WC, Ziajka PE 2002 Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors. Am J Cardiol 86:1123-1127
78. Schectman G, Hiatt J 1996 Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. Ann Intern Med 125:990-1000
79. Beigneux A, Hofmann AF, Young SG 2002 Human CYP7A1 deficiency: progress and enigmas. J Clin Invest 110:29-31
80. Superko HR, Greenland P, Manchester RA, Andreadis NA, Schectman G, West NH, Hunninghake D, Haskell WL, Probstfield JL 1992 Effectiveness of low-dose Colestipol therapy in patients with moderate hypercholesterolemia. Am J Cardiol 70:135-140
81. Gagné C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B, for the Ezetimibe Study Group 2002 Efficacy and safety of ezetimibe added to ongoing stalin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 90:1084-1091
82. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP, on behalf of the Ezetimibe Study Group 2002 Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 40:2125-2134
83. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Juttunen JK, Kaitaniemi P, Koskinen P, Mälkönen J, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA 1988 Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260:641-651
84. Sprecher DL 2000 Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review. Am J Cardiol 86(Suppl):46L-50L
85. Insua A, Massari F, Rodriguez Moncalvo JJ, Ruben Zanchetta J, Insua AM 2002 Fenofibrate or gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study. Endocrine Practice. 8:96-101
86. Packard KA, Backes JM, Lenz TL, Wurdeman RL, Destache CJ, Hilleman DE 2002 Comparison of gemfibrozil and fenofibrate inpatients with dyslipidemic coronary heart disease. Pharmacotherapy. 22:1527-1532
87. Yuan J, Tsai MY, Hunninghake DB 1994 Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis 110:1-11
88. Stalenhoef AF, deGraaf J, Wittekoek ME, Bredie SJ, Demacker PN, Kastelein JJ 2000 The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Atherosclerosis 153:129-138
89. 2002 A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis 162:363-371
90. Schweitzer M, Tessie D, Vlahos WD, Leiter L, Collet JP, McQueen MJ, Harvey L, Alaupovic P 2002 A comparison of pravastatin and gemfibrozil in the treatment of dyslipoprotein in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis 162:201-210
91. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Llinares E, Schaffer EJ, Schectman G, Wilt TJ, Wittes J, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group 1999 Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341:410-418
92. Diabetes Atherosclerosis Intervention Study Investigators 2001 Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357:905-910
93. Barbier O, Pineda Torra I, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B 2002 Pleiotrophic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22:717-726
94. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB, for the VA-HIT Study Group 2001 Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA 285:1585-1591
95. Otvos J, LDL and HDL particle subclasses are independent predictors of cardiovascular events in the Veterans Affairs HDL Intervention Trial. Prog 75th Scientific Session of the American Heart Association, Chicago, IL, 2002
96. Ballantyne CM, Carsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JPD, Stein EA 2003 Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163:553-564
97. Tavintharan S, Kashyap ML 2001 The benefits of niacin in atherosclerosis. Curr Atheroscler Rep 3:74-82
98. Knopp RH 2000 Evaluating niacin in its various forms. Am J Cardiol 86(Suppl):51L-56L
99. McKenney JM, Proctor JD, Harris S, Chinchili VM 1994 A comparison of the efficacy and toxic effects of sustained vs. immediate-release niacin in hypercholesterolemic patients. JAMA 271:672-677
100. Kashyap ML, McGovern ME, Berra K, Guyton JR, Kwiterovich Jr PO, Harper WL, Toth PDS, Favrot LK, Kerzner B, Nash SD, Bays HE, Simmons PD 2002 Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 89:672-678
101. Elam MB, Hunninghake DB, David KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA, for the ADMIT Investigators 2000 Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT Study: a randomized trial. JAMA 284:1263-1270
102. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP, for the Diabetes Multicenter Research Group 2002 Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med 162:1568-1576
103. Lakka H-M, Laaksonen DE, Lakka TA, Niskanen LE, Kumpusalo E, Tuomilehto J, Salonen JT 2002 The metabolic syndrome and total cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716
104. Ridker PM, Buring JE, Cook NR, Rifai N 2003 C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation 107:391-397
105. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, Martin J 2002 Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 24:378-396
106. Khan MA, St. Peter JV, Xue JL 2002 A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25:708-711
107. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI 2002 Effect of rosigiltazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-684
108. Hsueh WA, Law RE 2001 PRARγ and atherosclerosis. Effects on cell growth and movement. Arterioscler Thromb Vasc Biol 21:1891-1895
109. Sacks FM 2001 Lipid-lowering therapy in acute coronary syndromes. JAMA 285:1758-1760
110. Wright RS, Murphy JG, Bybee KA, Kopecky SL, LaBlanche J-M 2002 Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit. Mayo Clin Proc 77:1085-1092
111. Sacks FM, for the Expert Group on HDL Cholesterol 2002 The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 90:139-143
112. Yusuf S 2002 Two decades of progress in preventing vascular disease. Lancet 360:2-3
113. Athyros VG, Papageorgious AA, Athyrou VV, Demitriadis DS, Pehlivanidis AN, Kontopoulos AG 2002 Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. J Cardiovasc Risk 9:33-39
114. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG 1997 Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 80:608-613
115. McNeely MJ, Edwards KL, Marcovina SM, Brunzell JD, Motulsky AG, Austin MA 2001 Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: a 20-year prospective study. Atherosclerosis 159:471-481
116. Austin MA, McKnight B, Edwards KL, Bradley CM, McNeely MJ, Psaty BM, Brunzell JD, Motulsky AG 2000 Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation 101:2777-2782
117. Assmann G, Nofer J-R 2003 Atheroprotective effects of high-density lipoproteins. Annu Rev Med 54:321-341
118. Guyton JR 1998 Effect of niacin on atherosclerotic cardiovascular disease. Am J Cardiol 82:18U-23U
119. Gardner CD, Fortmann SP, Krauss RM 1996 Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276:875-881
120. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Hull LG, Sacks FM, Hennekens CH 1996 A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276:882-888
121. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després J-P 1997 Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 95:69-75
122. Marais AD 2000 Therapeutic modulation of low-density lipoprotein size. Curr Opin Lipidol 11:597-602
123. Otvos JD, Shalaurova I, Freedman DS, Rosenson RS 2002 Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis 160:41-48
124. Kontopoulos AG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H 1996 Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis 7:843-850
125. März W, Schamagl J, Abletshauser C, Hoffman MM, Berg A, Keul J, Wieland H, Baumstark MW 2001 Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with atherogenic lipoprotein phenotype. Circulation 103:1942-1948
126. McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML 2001 Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 88:270-274
127. Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ, Caslake MJ 2002 Influence of atorvastatin and simvastatin on apolipoprotein β metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis. 164:129-145
128. Austin MA, King MC, Vranizan KM, Krauss RM 1990 Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82:495-506
129. 2003 Heart disease and stroke statistics, 2003 update. Dallas: American Heart Association
130. Barrett-Connor E 1997 Sex differences in coronary heart disease: why are women so superior? The 1995 Ancel Keys Lecture. Circulation 95:252-264
131. Bittner V2001 Estrogens, lipids and cardiovascular disease: no easy answers. J Am Coll Cardiol 37:432-433
132. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613
133. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D 2000 Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med. 343:522-529
134. Welty FK 2001 Cardiovascular disease and dyslipidemia in women. Arch Intern Med 161:514-522
135. Buchwald H, Campos CT, Matts JP, Fitch LI, Long JM, Varco RL, and the POSCH Group 1992 Women in the POSCH trial: effects of aggressive cholesterol modification in women with coronary heart disease. Ann Surg 216:389-397
136. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto Jr AM 1998 Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279:1615-1622
137. Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, Letterer R, Limacher M, Moye LA, Rouleau Jk, Pfeffer MA, Braunwald E 1998 Effect of pravastatin on cardiovascular events in women after myocardial infarction: The Cholesterol and Recurrent Events (CARE) trial. J Am Coll Cardiol 32:140-146
138. Miettinen TA, Pyorala K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, Berg K, Pedersen T, Kjekshus J 1997 Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival study (4S). Circulation 96:4211-4218
139. Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kemper AM, Macfariane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Swomey C, Westerndorp RG on behalf of the PROSPER study group 2002 Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623-1630
140. LIPID Study Group 1998 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357
141. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, Houston-Miller N, Kris-Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Smith Jr SC, Washington R 1997 When to start cholesterol-lowering therapy in patients with coronary heart disease: a statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation 95:1683-1685
142. Andrews TC, Raby K, Barry J, Naimi CL, Allred E, Ganz P, Selwyn AP 1997 Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 95:324-328
143. Miura DS 2001 Controversies in the treatment of hypercholesterolemia in the elderly: who should be treated and how? Am J Geriatr Cardiol 10:152-158
144. Barzilay JI, Spiekerman CF, Kuller LH, Burke GL, Bittner V, Gottdiener JS, Brancati FL, Orchard TJ, O'Leary DH, Savage PJ 2001 Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders: The Cardiovascular Health Study. Diabetes Care. 24:1233-1239
145. Oberman A, Kreisberg RA 2002 Lipid management in older patients. Clin Geriatr 10:41-50
146. Williams MA, Fleg JL, Ades PA, Chairman BR, Miller NH, Mohiuddin SM, Ockene IS, Taylor CB, Wenger NK 2002 Secondary prevention of coronary heart disease in the elderly (with emphasis on patients ≥75 years of age). Circulation 105:1735-1743
147. Crouse 3rd JR, Byington RP, Hoen HM, Furberg CD 1997 Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 157:1305-1310
148. Hankey GJ 2002 Role of lipid-modifying therapy in the prevention of initial and recurrent stroke. Curr Opin Lipidol 13:645-651
149. Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, Ezekowitz M, Chaitman BR, Leslie SJ, Stern T, for the MIRACL Study Investigators 2002 Effects of atorvastatin on stroke with unstable angina or non-Q-wave myocardial infarction. A myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy. Circulation 106:1690-1695
150. Fries JF 1996 Physical activity, the compression of morbidity, and the health of the elderly. J R Soc Med 89:64-68
151. Tsimikas S, Witztum JL 2002 Shifting the diagnosis and treatment of atherosclerosis to children and young adults: a new paradigm for the 21st century. J Am Coll Cardiol 40:2122-2124
152. Strong JP, Malcon GT, McMahan CA, Tracy RE, Newman WP, Herderick EE, Cornhill JF 1999 Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 281:727-735
153. 1991 Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute
154. Williams CL, Hayman LL, Daniels SR, Robinson TN, Steinberger J, Paridon S, Bazzarre T 2002 Cardiovascular health in childhood: statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 106:143-160
155. Friedland O, Nemet D, Gorodnitsky N, Wolach B, Eliakim A 2002 Obesity and lipid profiles in children and adolescents. J Pediatr Endocrinol Metab 15:1011-1016
156. Nicklas TA, Dwyer J, Feldman HA, Luepker RV, Kelder SH, Nader PR 2002 Serum cholesterol levels in children are associated with dietary fat and fatty acid intake. J Am Diet Assoc 102:511-517
157. Clauss SB, Kwieterovich PO 2002 Long-term safety and efficacy of low-fat diets in children and adolescents. Minerva Pediatr 54:305-313
158. Lagstrom H, Jokinen E, Seppanen R, Ronnemaa T, Viikari J, Valimaki I, Venetoklis J, Myyrinmaa A, Niinikoski H, Lapinleimu H, Simell O 1997 Nutrient intakes by young children in a prospective randomized trial of a low-saturated fat, low-cholesterol diet. The STRIP Baby Project. Special Turku Coronary Risk Factor Intervention Project for Babies. Arch Pediatr Adolesc Med 151:181-188
159. Amundsen AL, Ose L, Nenseter MS, Ntanios FY 2002 Plant sterol ester-enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia. Am J Clin Nutr 76:338-344
160. West R 1999 Management of hyperlipidemia in children. In: Betteridge DJ, Illingworth DR, Shepherd J, eds. Lipoproteins in health and disease. London: Arnold; 1279-1284
161. McCrindle BW, Helden E, Cullen-Dean G, Conner WT 2002 A randomized crossover trial of combination pharmacogenic therapy in children with familial hyperlipidemia. Pediatr Res 51:715-721
162. Stein EA 2001 Statins in children. Why and when. Nutr Metab Cardiovasc Dis 11(Suppl 5):24-29
163. Athyros VG, Papageorgiou AA, Kontopoulos AG 2002 Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia. Atherosclerosis 163:205-206
164. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M 1998 Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234
165. Howard BV, Robbins DC, Sievers ML, Lee ET, Rhoades D, Devereux RB, Cowan LD, Gray RS, Welty TK, Go OT, Howard WJ 2000 LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL. The Strong Heart Study. Arterioscler Thromb Vasc Biol 20:830-835
166. Sacks FM, Tonkin AM, Craven T, Pfeffer MA, Shepherd J, Keech A, Furberg CD, Braunwald E 2002 Coronary heart disease in patients with low LDL-C. Benefit of pravastatin in diabetics and enhanced role for HDL-C and triglycerides as risk factors. Circulation 105:1424-1428
167. Tonelli M, Moyé L, Sacks FM, Kiberd B, Curhan G, for the Cholesterol and Recurrent Events (CARE) Trial Investigators 2003 Pravastatin for secondary prevention of cardiovascular events in persons with mild renal insufficiency. Ann Intern Med 138:98-104
168. Tsiodras S, Mantzoros C, Hammer S, Samore M 2000 Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy. A 5-year cohort study. Arch Intern Med 160:2050-2056
169. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, Sosman JM 2001 Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104:257-262
170. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, Greenberg AE, Janssen RS, and the HIV Outpatient Study (HOPS) Investigators 2002 Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360:1747-1748
171. Klein D, Hurley LB, Quesenberry Jr CP, Sideny S 2002 Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J AIDS 30:471-477
172. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA 2003 Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348:702-710
173. Kuritzkes DR, Currier J 2003 Cardiovascular risk factors and antiretroviral therapy. N Engl J Med 348:679-680
174. Manfredi R, Chiodo F 2001 Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect 42:181-188
175. Green M 2002 Evaluation and management of dyslipidemia in patients with HIV infection. J Gen Intern Med 17:797-810
176. Hui DY 2003 HIV protease inhibitors and atherosclerosis J Clin Invest 111:317-318
177. 2003 Three new drugs for hyperlipidemia. The Medical Letter 45:17-19